about
Contemporary management of stage I and II seminoma.The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer.Primary tracheal Ewing's sarcoma.Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas.Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection.Axial Skeletal Location Predicts Poor Outcome in Ewing's Sarcoma: A Single Institution Experience.Spermatocytic seminoma: a review.Stage II testicular seminoma: patterns of recurrence and outcome of treatment.The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis.Treatment options, prognostic factors and selection of treatment in stage I seminoma.Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy.Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.Management of stage I seminomatous testicular cancer: a systematic review.The relationship between external beam radiotherapy dose and chronic urinary dysfunction--a methodological critique.Delineating the inner bladder surface using uniform contractions from the outer surface under variable bladder filling conditionsTechnical Note: Method to correlate whole-specimen histopathology of radical prostatectomy with diagnostic MR imagingImproved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy.Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer.Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study.Clinical Characteristics and Outcomes of Late Relapse in Stage I Testicular Seminoma.MR elastography to measure the effects of cancer and pathology fixation on prostate biomechanics, and comparison with T 1, T 2 and ADC.Quality indicators in the management of bladder cancer: A modified Delphi study.An Analysis of Tumor- and Surgery-Related Factors that Contribute to Inadvertent Positive Margins Following Soft Tissue Sarcoma Resection.Prostate T(1) quantification using a magnetization-prepared spiral technique.Image guided dose escalated prostate radiotherapy: still room to improve.The effect of registration surrogate and patient factors on the interobserver variability of electronic portal image guidance during prostate radiotherapy.Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey.Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.Topotecan and cyclophosphamide in adults with relapsed sarcoma.PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors.The influence of time interval between preoperative radiation and surgical resection on the development of wound healing complications in extremity soft tissue sarcoma.The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours.Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma.Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance.Retroperitoneal hematoma following radical orchiectomy: Two casesOutcome following radiotherapy for head and neck basal cell carcinoma with 'aggressive' features.Clinical prostate T2 quantification using magnetization-prepared spiral imaging.The effect of the setting of a positive surgical margin in soft tissue sarcoma.
P50
Q30352886-88B83D7B-291A-438F-BAC6-BD172E9B1C33Q33470011-7300A952-FD8E-4255-AE15-D803DA242B42Q33702957-A9835989-0BA7-4BE1-80DF-F330821CFB10Q34608209-383DC24E-8343-4431-B8CC-8D4AB5B37A50Q34623315-37F6DE98-0BB8-4239-A37F-D9AA9672542AQ35608783-5FB35C6F-2ADB-4BC6-9D5E-14A0C2578EA8Q35710479-76CD781F-5830-430C-8375-E60AB6A09547Q35776550-6F347643-C335-493C-8939-4C4F0B4E03ECQ36631959-F6D3DBDF-0B8B-4F3C-A045-656E325D2A03Q36698951-BDACBDF9-C9BE-4245-A4B1-5491567ADBF1Q36984325-343EF04F-B54F-4A78-9AE3-3459FC4D3405Q37350871-7860904D-B832-45CD-BCAB-46419EF20B74Q37602353-A3009C3D-F650-44A3-BCF1-C132C828D00AQ37785334-BC5BAB44-1CF0-4B17-AFFB-CBDFA34B638AQ38269778-5AE12BB4-E68F-4E77-8EBC-2FA07762B7ADQ38273485-F1099ACB-513C-4F74-9F5A-9726C1E3E673Q38824271-ACCB36FB-3197-480F-8738-B2698C2280B3Q38831047-025BEB2A-0B82-41E7-ABBA-AEC64C5FB666Q38836916-F3CE8D9F-D499-471B-94DD-19B11E91DCD8Q38842793-BF0ABD80-0718-46C3-8324-00EA339598A3Q38875307-491A3D56-6EBA-460D-A17F-018012B98D60Q39018197-50F69447-DC96-4DCD-8C34-B6D5BDC79A1AQ39033545-13DDEE25-C9CC-4C34-B7C4-750CF5DA43D5Q39204213-3E61B222-F050-4A12-852E-C1715323D73CQ39788835-53089186-3E34-4EFC-A807-C235CCB5E538Q39932645-503D3021-2A8F-423F-8D9A-722D20A1026EQ39951101-C855E5A7-4B5A-4281-B0C9-F8A4BE7E3468Q40024417-5B56F7B5-C36C-4A6B-ACCB-1561CE3DF36CQ40194362-14B76A5C-D2F1-48BC-A37B-286FB2095EB6Q40278945-F2BA911E-E1D9-4BE7-9599-B4DF5213B502Q40738452-45AD8C53-7C45-406F-BB33-2B13CC25F5AEQ41139402-7CD3FB5B-8D67-493E-983E-1B8F674DC52DQ41198773-6B3170E0-4022-4737-BBE9-B57BFBE4CB61Q41259756-076D040D-EC23-4226-A4A3-D4DF6720AFFAQ41963479-5C172A67-1FBC-4984-AAEC-72C26FFE888DQ42254931-923930FF-269F-419D-B9C8-D167F78DF91AQ42328207-0D12B278-3651-45CE-861C-79F23176F628Q42513509-FB5815A7-7B09-4A58-AC4A-AAED62B6D5C4Q43687268-8330B552-DB86-4B05-B56C-CA18ECA1ED92Q43991921-99107F54-671D-4A45-A813-4B39F34046DB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter W Chung
@ast
Peter W Chung
@en
Peter W Chung
@es
Peter W Chung
@nl
type
label
Peter W Chung
@ast
Peter W Chung
@en
Peter W Chung
@es
Peter W Chung
@nl
prefLabel
Peter W Chung
@ast
Peter W Chung
@en
Peter W Chung
@es
Peter W Chung
@nl
P106
P1153
7201442831
P31
P496
0000-0002-3815-7703